MTVA today
$1.33-$0.11 (-7.64%)close Nov 12, 2026Trend
DailyUptrend (starting)
4 hourBearish
1 hourSymmetric Triangle
15 minStrong Bearish
5 minExpanding
Daily trend turns down below $0.97
Key levels
Resistance$1.78
Resistance$1.45
Support$1.20
Support$1.02
Latest news & SEC filings
ProductMetaVia says drug candidate lowers uric acid, liver fat
ProductMetaVia Phase 1 data show DA-1726 lowered a biomarker versus placebo at 16 weeks
All MTVA news →About MetaVia
MetaVia is a clinical-stage pharmaceutical company that develops drug candidates for metabolic and other diseases. Its main product candidates are two investigational therapies being studied in preclinical and clinical trials. The company relies on third parties for manufacturing and on contract research organizations for conducting its studies. It operates primarily in the United States and has not yet received marketing approval for any product.
Based on the company's 10-K filed Mar 26, 2026.
Nasdaq · Healthcare
MetaVia Inc. (MTVA)
What Is the Price Target for MTVA?
SEPT Low Target
$0.00
SEPT Mid Target
$0.00
SEPT High Target
$0.00
Analyst Consensus
$0.00
Is MTVA a Buy or Sell Right Now?
AI-Powered Trading Signals
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy for MTVA.
Start Free Trial →Is MTVA Overvalued or Undervalued?
Valuation Verdict
UNDERVALUED
Methods Used
P/B
Fair Value
$2.96
4
Moat Score
NONE
1/9
Piotroski Score
-22.0
Altman Z-Score
What Is Smart Money Doing with MTVA?
Insider Signal
NEUTRAL
0 buys / 0 sells (90d)
Congress Signal
NEUTRAL
0 buys / 0 sells (90d)
Institutional
N/A
Short Squeeze Risk
LOW
Signal: NEUTRAL
Recent Insider Activity
| Name | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
| Tursi James Patrick | director | Buy | 17,186 | - | Jun 8, 2026 |
| STRICKLAND D GORDON | director | Buy | 17,186 | - | Jun 8, 2026 |
| Salsbury Michael | director | Buy | 17,186 | - | Jun 8, 2026 |
| GROVES JASON L | director | Buy | 17,186 | - | Jun 8, 2026 |
| KOVEN ANDREW I | director | Buy | 17,186 | - | Jun 8, 2026 |
| Glickman Mark A | director | Buy | 17,186 | - | Jun 8, 2026 |
Track Smart Money Across 4,000+ Stocks
Insider trades, congress trades, institutional flows, and short interest — updated daily with real-time alerts.
See All Smart Money Signals →MTVA Growth Story
Revenue YoY
N/A%
3yr Revenue CAGR
N/A%
EPS Growth YoY
81.22%
FCF Growth YoY
36.5%
Revenue Trend
UNKNOWN
Dark Pool Trades for MTVA
PREVIEWSEPT Investing tracks real-time dark pool institutional trades for MTVA, including block trade sizes, dollar values, and buy/sell side classification. Dark pool trades reveal where institutional investors are positioning before moves become visible on public exchanges.
| Time | Price | Size | Value | Side |
|---|---|---|---|---|
| 18:54:11 | $1.33 | 1,500 | $$2K | BUY |
| 17:55:49 | $1.32 | 2,000 | $$3K | SELL |
| 17:47:26 | $1.30 | 6,100 | $$8K | SELL |
| 14:34:05 | $1.40 | 1,100 | $$2K | SELL |
| 21:23:39 | $1.38 | 1,000 | $$1K | SELL |
5 dark pool trades shown · $$15K preview volume
Real-time institutional flow, block trades, and net positioning
Full AI Research Report
SEPT's Trading AI has generated a free, downloadable PDF research report for MetaVia Inc. (MTVA) covering valuation analysis, financial health assessment, growth projections, smart money tracking, earnings and key price levels. For research only, not investment advice.
Report includes: PDF download, detailed valuation models (DCF, P/E, EV/EBITDA), institutional flow analysis, congress and insider trade tracking, FinBERT news sentiment (3 articles analyzed), and SEC filing intelligence...
AI-Powered Trading Signals.
Trained on trillions of real market data to read price action and give you a simple, emotionless trading strategy. SEPT tells you when to buy, when to sell, and grades every stock so you never trade blind.
Try SEPT Free for 7 Days →MTVA — frequently asked questions
What is MTVA stock price today?
MetaVia Inc. (MTVA) is at $1.33, down 7.64% (-$0.11) at the Nov 12, 2026 close.
Why is MTVA stock moving today?
Latest MTVA news — Nov 12, 2026: MetaVia says drug candidate lowers uric acid, liver fat · Nov 12, 2026: MetaVia Phase 1 data show DA-1726 lowered a biomarker versus placebo at 16 weeks
What do analysts rate MTVA?
Analyst ratings for MTVA: 0 Buy, 3 Hold, 0 Sell — consensus Hold.
Did MTVA beat earnings?
MTVA last reported on Aug 6, 2026: EPS -$0.90 vs -$0.82 expected — a miss of 9.8%.
Does MTVA pay a dividend?
MTVA does not currently pay a dividend.
What are MTVA support and resistance levels?
Support: $1.20, $1.02. Resistance: $1.45, $1.78, $2.32.
What are insiders doing with MTVA?
Insider activity: NEUTRAL, 0 buys and 0 sells in the last 90 days.
What is the latest news on MTVA?
Nov 12, 2026: MetaVia says drug candidate lowers uric acid, liver fat · Nov 12, 2026: MetaVia Phase 1 data show DA-1726 lowered a biomarker versus placebo at 16 weeks